Excelra

Excelra Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market.

The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyze large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients including 15 of the top 20 large Pharma companies.

27/03/2026

| What if the key to the next NSCLC breakthrough was already buried in existing clinical data, just waiting to be found?

For immuno-oncology teams, that's not a hypothetical. It's the reality they work in every day. Read the full case study: https://na2.hubs.ly/H04xt3_0

Excelra uncovered exactly that. By weaving together text mining, expert-led curation, and rigorous clinical analysis, we transformed scattered trial data into a living, structured landscape of NSCLC immunotherapy evidence. Biomarker correlations surfaced. PD-L1 expression patterns became clear.
Treatment efficacy across therapy lines told a coherent story for the first time.

Excelra is proud to sponsor Drug Discovery Chemistry 2026! https://na2.hubs.ly/H04v6Vh0Join us in San Diego as we explor...
25/03/2026

Excelra is proud to sponsor Drug Discovery Chemistry 2026! https://na2.hubs.ly/H04v6Vh0

Join us in San Diego as we explore how data, AI, and advanced informatics are reshaping early drug discovery, accelerating the identification of novel drug candidates and optimizing small molecules for therapeutic impact.

đź“Ť San Diego, CA
🗓️ April 13–16, 2026
Find us at Booth #414

Attending? We'd love to connect. Drop by and let's talk drug discovery!

Too much multi-omics data. Not enough insight.See how R&D teams cut time to insight by 60%: https://na2.hubs.ly/H04rzXK0...
23/03/2026

Too much multi-omics data. Not enough insight.
See how R&D teams cut time to insight by 60%: https://na2.hubs.ly/H04rzXK0

The problem isn't data. It's finding the right data, fast enough to matter.
Genomics. Proteomics. Transcriptomics. Legacy systems. Live datasets. All siloed. All slowing you down.

A centralized multi-omics data platform changes that, giving scientists and R&D leaders instant access to catalogued, queryable data across every informatics system they work in.

Your data shouldn't be the bottleneck. Your platform should be the accelerator.

Hundreds of papers. Dozens of compounds. Multiple tumor types.Yet pharmacodynamic biomarker insights for MDM2 inhibitors...
20/03/2026

Hundreds of papers. Dozens of compounds. Multiple tumor types.
Yet pharmacodynamic biomarker insights for MDM2 inhibitors remain scattered, making it difficult for oncology teams to connect evidence across studies.

Read the full case study: https://na2.hubs.ly/H04pQv30

Excelra brought this fragmented knowledge together systematically curating literature, identifying MDM2 compounds, and extracting PD biomarker insights across preclinical and clinical research.
The outcome was a structured dataset that makes it easier for researchers to discover biomarker insights and accelerate oncology research.

Identifying the right patient subgroups early in clinical development remains a key challenge in autoimmune therapy rese...
17/03/2026

Identifying the right patient subgroups early in clinical development remains a key challenge in autoimmune therapy research. Explore how Excelra’s AI-driven multi-omics analytics enables more precise patient stratification: https://na2.hubs.ly/H04kJQj0

By applying machine learning to integrated multi-omics datasets, Excelra identified 21 predictive biomarkers, helping define clearer responder subgroups and supporting more targeted follow-up trials.

Enabling data-driven biomarker discovery to improve patient stratification and clinical trial outcomes.

Struggling with fragmented, hard-to-find OMICs datasets across multiple systems? Learn how a unified, metadata-driven pl...
13/03/2026

Struggling with fragmented, hard-to-find OMICs datasets across multiple systems? Learn how a unified, metadata-driven platform solved this challenge: https://na2.hubs.ly/H04gSnP0

By integrating legacy and ongoing OMICs data across ELNs, internal clouds, and vendor systems, the platform enabled fast, parameter-based search, real-time access, and role-specific views, cutting data retrieval time, improving traceability.

This case study shows how centralized OMICs data platforms and standardized metadata unlock research agility, cross-team collaboration, and regulatory confidence at scale.

Struggling with fragmented data slowing down your antibody discovery? Discover how integrated biologics analytics can ac...
11/03/2026

Struggling with fragmented data slowing down your antibody discovery? Discover how integrated biologics analytics can accelerate candidate nomination: https://na2.hubs.ly/H04d0Yg0

By harmonizing epitope, developability, and immunogenicity data into a single pipeline, cross-functional teams can make faster, more confident decisions, accelerating biologics lead selection by 25%.

Excelra helps unify critical biologics data streams to support smarter, faster nomination of antibody-based therapy candidates.

&D

Patent intelligence shouldn’t slow drug discovery; it should accelerate it. Medicinal chemists can now bring curated pat...
11/03/2026

Patent intelligence shouldn’t slow drug discovery; it should accelerate it.

Medicinal chemists can now bring curated patent compound data directly into their SAR workflow using GOSTAR™ within Discngine Ideation SAR Slides. Simply enter a Patent ID and instantly access structures, biological activity, and annotation- ready for SAR exploration without switching tools.

Go from Patent ID → SAR insight → design decisions in minutes. Less friction. Faster insights. Better-informed drug discovery.

Read the blog to see how this workflow helps accelerate patent-driven SAR analysis: https://na2.hubs.ly/H04d3Cc0

Struggling to identify new indications from fragmented clinical and real-world data?Discover how Excelra’s bioinformatic...
09/03/2026

Struggling to identify new indications from fragmented clinical and real-world data?
Discover how Excelra’s bioinformatics-driven data intelligence accelerates indication expansion: https://na2.hubs.ly/H0494Mz0

By integrating clinical trials, literature, and real-world evidence across 100,000+ patient samples, Excelra enabled rapid hypothesis generation, supporting the launch of 5 new GI trials in under 12 months.

Turn fragmented clinical and real-world data into actionable insights to identify and validate new indications faster.

What happens when a drug discovery database grows by over a million SAR data points? With the latest expansion of GOSTAR...
06/03/2026

What happens when a drug discovery database grows by over a million SAR data points?

With the latest expansion of GOSTARᵀᴹ Small Molecules, researchers gain access to 1M+ new SAR records and 400K+ compounds, along with broader coverage across ADMET data, targets, patents, and literature, strengthening the data foundation for discovery and optimization.

Swipe through the carousel to explore how these updates enhance SAR analysis, medicinal chemistry decisions, and data-driven drug design.

đź”— Learn more: https://na2.hubs.ly/H046_w20

05/03/2026

| Still relying on prostate cancer screening approaches that can result in unnecessary invasive biopsies? See how Excelra addressed this challenge: https://na2.hubs.ly/H044PLY0

We developed an AI-powered diagnostic framework using heterogeneous biomarker analysis and ensemble machine learning models to accurately assess prostate cancer status and support automated biopsy decision-making.

Read the full case study to learn how AI-driven diagnostics can improve screening accuracy while reducing clinical risks.

Address

7th Floor Wing B
Uppal
500039

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm

Telephone

+91 40 6707 3333

Website

Alerts

Be the first to know and let us send you an email when Excelra posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Excelra:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram